Significantly, an elevated rate of toxicities has been observed for CAR T therapies targeting TAAs including ERBB2 in metastatic colon cancer and carbonic anhydrase IX (CAIX) in renal cell carcinoma apparently accredited to the common expression of targeted antigens by both cancer and normal cells [114, 115]. This evidence concerns the gene CA9 and cancer.